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ABSTRACT
The EC (entorhinal cortex) is fundamental for cognitive and
mnesic functions. Thus damage to this area appears as a
key element in the progression of AD (Alzheimer’s disease),
resulting in memory deficits arising from neuronal and
synaptic alterations as well as glial malfunction. In this
paper, we have performed an in-depth analysis of astroglial
morphology in the EC by measuring the surface and volume
of the GFAP (glial fibrillary acidic protein) profiles in a triple
transgenic mouse model of AD [3xTg-AD (triple transgenic
mice of AD)]. We found significant reduction in both the
surface and volume of GFAP-labelled profiles in 3xTg-AD
animals from very early ages (1month)when compared with
non-Tg (non-transgenic) controls (48 and 54%, reduction
respectively), which was sustained for up to 12 months (33
and 45% reduction respectively). The appearance of Ab
(amyloid b-peptide) depositions at 12 months of age did not
trigger astroglial hypertrophy; nor did it result in the close
association of astrocytes with senile plaques. Our results
suggest that the AD progressive cognitive deterioration
can be associated with an early reduction of astrocytic
arborization and shrinkage of the astroglial domain, which
may affect synaptic connectivity within the EC and between
the EC and other brain regions. In addition, the EC seems to
be particularly vulnerable to AD pathology because of the
absence of evident astrogliosis in response to Ab accumula-
tion. Thus we can consider that targeting astroglial atrophy
may represent a therapeutic strategy which might slow
down the progression of AD.
Key words: Alzheimer’s disease, astrocyte, dementia,
entorhinal cortex, glial fibrillary acidic protein (GFAP),
memory.
INTRODUCTION
The EC (entorhinal cortex), a part of the temporal cortex, is
involved in mnesic processes by establishing the cortico-
hippocampal circuits. The EC is divided into superficial (I–III)
and deep layers (IV–VI) that show differential anatomical and
functional organization (Suzuki and Amaral, 1994; Witter
and Amaral, 2004). The superficial layers are the main reci-
pient of intracortical information and the major output
source to the HC (hippocampus), whereas the deep layers are
mainly responsible for the projections to cortical regions
(Figure 1; Suzuki and Amaral, 1994; Witter and Amaral,
2004). The neurons from the EC layer II terminate in the
middle and outer molecular layer of the DG (dentate gyrus)
and send collaterals to the hippocampal CA2 and CA3 fields
(Witter et al., 1989; Tamamaki and Nojyo, 1993; Suzuki and
Amaral, 1994). Layer III neurons project mainly to the CA1
and subiculum, which in turn feedback to layer V of the EC
(Naber et al., 2001). Functionally, activation of the EC and
persistent neuronal activity in the EC are involved in the
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asnneuro.org / Volume 3 (5) / art:e00071 271process of working memory (Ranganath et al., 2003; Fransen,
2005; McGaughy et al., 2005). The EC is also essential for
memory consolidation (Remondes and Schuman, 2004; Craig
and Commins, 2005) and spatial navigation and memory
(Fyhn et al., 2004; Moser et al., 2008).
Entorhinal dysfunction is involved in several brain diseases
that compromise cognitive and memory functions, including
AD (Alzheimer’s disease) (Braak and Braak, 1991; Kril et al.,
2002; Schwarcz and Witter, 2002; Cunningham et al., 2006).
The AD is an irreversible neurodegenerative disease accom-
panied by cognitive/memory impairments, which is the most
common cause of progressive dementia in elderly people
(Braak and Braak, 1991; Braak et al., 1999; Harciarek and
Jodzio, 2005). AD is characterized by the appearance of SPs
(senile plaques) representing extracellular Ab (amyloid b-
peptide) depositions (Nagele et al., 2004) and NFTs (neurofibril
tangles) consisting of abnormally hyperphosphorylated tau
protein, the latter being a major microtubule-associated pro-
tein (Schneider and Mandelkow, 2008). The EC is affected very
early by AD pathology; it is arguably the first brain region
experiencing Ab accumulation (Braak and Braak, 1991, 1997;
Thal et al., 2000). Similarly, the NFTs appear in the trans-
entorhinal region and in the EC at the early stages of AD (Braak
stages I/II) and are widespread in the EC at middle Braak stages
(limbic stages III/IV) (Solodkin et al., 1996; Braak and Braak,
1997). Concomitant with the presence of Ab and NFTs in the
EC, this cortical region undergoes severe volume decrease that
also affects its major projection target, the HC (Du et al., 2001;
Halliday et al., 2003; Whitwell et al., 2008). Profound neuronal
loss, mainly in layer II, also occurs in AD concomitantly with
mild cognitive impairment (Gomez-Isla et al., 1996; de Toledo-
Morrell et al., 2000; Du et al., 2001; Rodrigue and Raz, 2004).
The AD-related neuronal loss and atrophy of the EC are
well documented in human patients (Gomez-Isla et al., 1996;
Calhoun et al., 1998; de Toledo-Morrell et al., 2000; Du et al.,
2001; Kordower et al., 2001; Ribe et al., 2005). However, little
is known about AD-associated changes in EC astroglia. Post-
mortem studies have revealed an increase in GFAP (glial
fibrillary acidic protein) protein levels as well as in the
number of GFAP-positive astrocytes within the EC, which
seems to be associated with the Ab load (Muramori et al.,
1998; Porchet et al., 2003). Recently, we reported the
concomitant occurrence of astroglial atrophy and astrogliosis
in the HC of the transgenic mice model of AD. The atrophy
appears as a generalized process, whereas astrogliosis was
triggered by developing SPs and Ab aggregates (Rodrı ´guez
et al., 2009b; Heneka et al., 2010; Olabarria et al., 2010;
Verkhratsky et al., 2010; Rodrı ´guez and Verkhratsky, 2011). In
the present paper, we extended our analysis of AD-associated
changes in astroglia to the EC.
MATERIALS AND METHODS
All animal procedures were carried out in accordance with
the United Kingdom Animals (Scientific Procedures) Act of
1986 under license from the Home Office. All efforts were
made to reduce the number of animals by following the 3R’s.
Animal models
The generation of 3xTg-AD (triple transgenic mice of AD)
mice has been well described (Oddo et al., 2003a, 2003b;
Billings et al., 2005; Rodrı ´guez et al., 2008; Rodrı ´guez et al.,
2009a, 2009b). The 3xTg-AD mice were derived from mixed
129/C57BL6 mice, which harbour APPswe, PS1M146V and
TauP301L mutations, and the same spatiotemporal progres-
sion of amyloid and tau protein pathology in human AD. The
non-Tg (non-transgenic) control mice were from the same
strain and the same genetic background. All 3xTg-AD and
non-Tg littermates were from homozygous breeders. Mice
were grouped by gender and genotype, housed under
controlled temperature and 12 h light/12 h dark cycles with
ad libitum access to food and water.
Fixation and tissue processing
Aspreviouslydescribed (Olabarriaetal.,2010),male3xTg-ADat
1, 3, 6, 9 and 12 months of age (n55, 4, 4, 5 and 5 respectively)
and their age-corresponding non-Tg controls (n54, 4, 4, 5, 5
respectively) were anaesthetized with sodium pentobarbital
(50 mg/kg) intraperitoneally. The brains were fixed by aortic
arch perfusion of 3.75% acrolein (25 ml; TAAB, UK) in 2%
(w/v) paraformaldehyde (Sigma,St. Louis, MO, U.S.A.) and 0.1 M
PB (phosphate buffer) at pH 7.4, followed by 75 ml of 2%
paraformaldehyde. Brains were removed, cut into 2–3 mm
Figure 1 Schematic illustration of entorhinal inputs to the HC
In brief, the superficial layers (I–III) project to the hippocampal formation and
subiculum,whilethedeeplayers(V/VI)receivereciprocalinputsfromtheseareas.
Meanwhile, deep layers also innervate to parahippocampal areas and the HC.
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formaldehyde for 24 h and sectioned at 40–50 mmw i t ha
vibrating microtome (VT1000S; Leica, Milton Keynes, U.K.).
Free-floating sections in 0.1 M PB were collected and stored in
a cryoprotectant solution containing 25% sucrose and 3.5%
glycerol in 0.05 M PB at pH 7.4. Coronal sections at levels
22.30 mm/23.88 mm [LEC (lateral entorhinal cortex)] poster-
ior to Bregma were selected for immunohistochemistry
according to the mouse brain atlas of Paxinos and Franklin
(2004).
Antibodies
To detect and determine the changes in the astrocytic
cytoskeleton in the EC, we used a monoclonal mouse
antiserum against GFAP (anti-GFAP; Sigma–Aldrich;
#G3893). For the identification of Ab aggregation as well
as the relation of astrocytic cytoskeleton alteration with Ab,
we used a polyclonal rabbit anti-GFAP serum (Sigma–Aldrich;
#G9269) and a monoclonal mouse antiserum against amino
acid residues 1–16 of Ab, which reacts with abnormally
processed isoforms and precursor form of Ab [EFRHDS; anti-
Ab 6E10 (SIG-39320), Signet Laboratories, Dedham, MA,
U.S.A.]. For the detection of NFTs, we used a monoclonal
mouse antiserum against PHF (paired helical filament) tau
protein, which recognizes phosphorylated Ser-202/Thr-205 of
tauprotein(Innogenetics, Zwijndrecht, Belgium).The immuno-
labelling pattern we obtained with this antibody is equivalent
to that obtained previously in different brain regions (Oddo
et al., 2003a). Positive and negative control immunohisto-
chemistry was used to test non-specific labelling and/or cross-
reaction between antisera derived from different host species,
showing no immunoreactivity (data not shown). The specificity
of these antisera was confirmed by immunohistochemistry and
Western blotting in previous papers (Goedert 1995; Halliday
et al., 1996; Rodrı ´guez et al, 2008).
Immunocytochemistry
The procedure for immunocytochemistry was as described
previously (Olabarria et al., 2010; Noristani et al., 2010). All
sections from both non-Tg and 3xTg-AD groups at different
ages were processed at the same time using precisely the
same experimental conditions to minimize methodological
variability. Sections were pretreated with 30% (v/v) methanol
and 3% H2O2 in 0.1 M PB for 30 min and subsequently a 1%
sodium borohydride (Sigma–Aldrich) solution for 30 min.
After washing with PB profusely, sections were then rinsed
with 0.1 M TS (Tizma-based saline; Sigma–Aldrich), followed
by incubation in 0.5% BSA (Sigma–Aldrich) and 0.25%
Triton X-100 (Sigma) for 30 min. The sections were incubated
in 0.1% BSA in 0.1 M TS at pH 7.6 and 0.25% Triton X-
100 containing the following antibodies: monoclonal mouse
anti-GFAP (1:5000; Sigma), monoclonal mouse anti-Ab
(1:1000; Covance, Emeryville, CA, U.S.A.) or monoclonal
mouse anti-PHF tau protein (1:1000; Innogenetics) at room
temperature (RT) (20–25˚C) for 48 h. The sections were rinsed
with TS and incubated in biotinylated horse anti-mouse
IgG (1:200; Vector Laboratories, Peterborough, U.K.) at
RT for 1 h. After rinsing with TS for 30 min, sections were
incubated with avidin–biotin peroxidase complex (Vector
Laboratories). The peroxidase reaction was carried out by
incubation with a solution containing 0.022% DAB (diami-
nobenzidine; Aldrich) or 0.003% H2O2, or the SG peroxidase
substrate kit (Vector Laboratories) for 5 min. Sections were
then dehydrated in ascending concentration of ethanol
(50, 70, 80, 90, 95 and 100%) and subsequently xylene, and
then permanently coverslipped with the use of Entellan
(Merck).
For single fluorescent labelling, the sections were then
incubated for 48 h at RT in the primary antibody solution as
mentioned above. Sections were then rinsed with 0.1 M TS and
incubated in secondary solution containing FITC-conjugated
goat anti-mouse IgG (1:100; Jackson Immunoresearch,
Baltimore Pike, PA, U.S.A.) for 1 h at RT.
For dual labelling, the sections were incubated for 48 h at
RT in a primary antibody cocktail containing (i) monoclonal
mouse anti-Ab antibody (1:1000; Covance) and (ii) rabbit
anti-GFAP (1:5000; Sigma) simultaneously. Sections were
washed with 0.1 M TS and incubated in rhodamine [TRITC
(tetramethylrhodamine b-isothiocyanate)]-conjugated goat
anti-rabbit for the detection of GFAP, followed by rinsing
with TS. Subsequently, the sections were incubated in FITC-
conjugated goat anti-mouse IgG (Invitrogen, Paisley, U.K.) for
the detection of Ab. All the sections were mounted in an
aqueous medium (Vectashield; Vector Laboratories).
Morphological analysis of the astrocytic
cytoskeleton
GFAP-positive astrocytes (n530–35 in single fluorescent
labelling experiments) throughout the layer of the LEC were
imaged by using confocal microscopy (Leica SP5, Mannheim,
Germany) with 0.2 mm z-step size. Parallel confocal planes
were superimposed and Cell Analyst program (Chvatal et al.,
2007) was used for analysis. Five digital filters (average 363,
convolution, gauss 565, despeckle, simple objects removal)
with a threshold of 50 were used to determine the surface
and volume of the GFAP-positive astrocytic cytoskeleton.
When analysing astroglial morphology in relation to Ab
plaques, all cells with somata within 50 mm from the plaque
border were regarded as plaque associated, and cells with
somata located more distantly (.50 mm) as cells not asso-
ciated with plaques (Olabarria et al., 2010).
GFAP-IR (glial fibrillary acidic protein-
immunoreactive) cell count in the EC
To determine the Nv (numerical density) of GFAP-IR astro-
cytes in the EC, we counted the number of GFAP-IR
astrocytes throughout the layers of the whole LEC, an area
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273of 435000 mm
2 in coronal sections with 40 mm thickness in
t h r e eo rf o u rr e p r e s e n t a t i v en on-consecutive sections.
Confocal stack images were used for this purpose. GFAP-IR
astrocytes were intensely labelled against dark background,
which made them easy to identify with equal chances of
being counted. The analysis was performed blindly with
regard to mouse genotype.
Statistical analysis
Data are expressed as means¡S.E.M. The paired or unpaired
Student’s t test was used to examine differences in the Nv,
surface, volume and somata volume of GFAP-labelled cells
between 3xTg-AD and non-Tg animals, using Graphpad Prism
(GraphPad Software, La Jolla, CA, U.S.A.). P(0.05 was
considered statistically significant.
RESULTS
GFAP-IR cells were widely distributed throughout the EC of
both non-Tg and 3xTg-AD mice (Figures 2A–2F), with layers I
and VI being the ones showing more GFAP-IR cells and
stronger immunoreactivity (Figures 2A and 2B). GFAP-IR
showed multiple branched processes extending in different
directions from elongated cell bodies (Figures 3D–3G).
Astrocytic cytoskeletal atrophy in 3xTg-AD mice
From 1 month of age, we observed morphological remodelling
of EC astrocytes in 3xTg-AD mice compared with non-Tg
animals. The astrocytes in 3xTg-AD animals had reduced
primary branches (on average by 26%) originating from the
soma and a markedly reduced presence of secondary processes
extending from the primary branches (reduced by 30% on
average), as well as distal ramifications (reduced by 45%;
Figures 3D–3G). These changes indicate a morphological
atrophy which was further confirmed by a significant decrease
in both the surface and volume of GFAP profiles in the EC of
3xTg-AD animals when compared with non-Tg controls
(Figures 3A and 3B). At younger ages (1 month), astrocytes
of 3xTg-AD mice showed a significant decrease in GFAP
surface when compared with the control. The surface area
of GFAP-IR profiles was reduced by 48% (378.45¡64.56 mm
2
compared with 728.47¡96.67 mm
2; P50.017; Figure 3A). The
volume of GFAP-IR cells in 3xTg-AD was reduced by 54%
(115.38¡25.82 mm
3 compared with 252.94¡32.73 mm
3;
P50.012; Figure 3B). This atrophic glial appearance was sus-
tained through all ages up to 12 months (Figures 3A and 3B).
This reduction was significant at 3 and 6 months of age;
the surface area was decreased by 44 and 39% (378.56¡
64.53 mm
2 compared with 680.20¡53.70 mm
2, P50.036;
354.68¡67.74 mm
2 compared with 581.26¡70.13 mm
2,
P50.025 respectively; Figure 3A). The volume of GFAP-IR cells
decreased by 42 and 42% respectively (130.25¡25.82 mm
3
compared with 224.32¡18.80 mm
3, P50.0490;
116.15¡25.63 mm
3 compared with 200.64¡31.07 mm
3,
P50.025 respectively; Figure 3B). However, from 9 months
of age onwards the degree of atrophic changes became
somewhat less pronounced because of parallel atrophic
changes developing in healthy aged controls. At 9 months of
age, the surface and volume of astrocytes in 3x-Tg-AD animals
were reduced, compared with the control, by 26%
(391.04¡30.75 mm
2 compared with 529.47¡48.21 mm
2,
Figure 2 Comparison of GFAP-IR cell distribution and density in the EC of
non-Tg and 3xTg-AD animals
Bright-field micrographs show the distribution of GFAP-IR astrocytes in the
EC of non-Tg and 3xTg-AD animals (A and B respectively). Confocal imaging
shows the organization of GFAP-IR astrocytes in the EC of non-Tg and 3xTg-
AD animals at 1 month (C and D respectively) and 12 months (E and F
respectively) at higher magnification. The histogram shows the Nv (number of
cells per mm
3) of GFAP-IR cells in the EC of 3xTg-AD and non-Tg controls (G).
Results are means¡S.E.M.
C.-Y. Yeh and others
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3 compared with
174.71¡15.41 mm
3, P50.014) respectively (Figures 3A and
3B). Likewise, at 12 months of age the decrease in surface
and volume was 33% (387.73¡47.75 mm
2 compared with
578.16¡84.46 mm
2; P50.021; Figure 3B) and 45%
(130.73¡14.93 mm
3 compared with 200.13¡25.18 mm
3;
P50.017) respectively (Figures 3A and 3B).
This generalized atrophy was also confirmed by a parallel
and significant decrease in the somata volume of GFAP-IR
astrocytes at a very early age (1 month) (41.63¡7.43 mm
3
compared with 71.69¡7.68 mm
3; P50.027; Figure 3C)
when compared with control mice. However, at later ages,
this decrease in somata volume persisted but became
insignificant when compared with non-Tg due to a parallel
decrease in non-Tg animals.
Layer-specific astrocytic atrophy during AD
We found a significant decrease in GFAP-IR cell surface areas
in layers II, III and VI of 3xTg-AD animals when compared with
controls from 1 month of age by 57% (323.57¡53.89 mm
2
compared with 769.28¡180.91 mm
2; P50.035), 45%
(305.36¡70.05 mm
2 compared with 564.42¡62.21 mm
2;
P50.031) and 56% (416.65¡87.62 mm
2 compared with
964.04¡118.84 mm
2; P50.007; Figure 4A) respectively. This
decrease in the GFAP surface was also paralleled by a reduction
in the cell volume in all layers: a reduction in volume of 66% in
layer II (84.78¡17.82 mm
3 compared with 251.43¡65.01
mm
3; P50.028), 68% in layer III (59.57¡16.16 mm
3 compared
with 187.70¡26.64 mm
3; P50.004) and 71% in layer VI
(132.08¡44.52 mm
3 compared with 360.13¡38.71 mm
3;
P50.0072; Figure 4B). However, we did not find any
significant difference in the other layers, layers I and V.
However, at middle age (6 months), these atrophic changes
in surface and volume occurred only in layers II and V. The
surfacedecreased by 38%(320.53¡71.52 mm
2 compared with
520.03¡79.62 mm
2; P50.021) and 41% (386.35¡97.00 mm
2
comparedwith650.50¡70.60mm
2; P50.004)inlayersIIand V
respectively (Figure 4C); the volume decreased by 45%
(93.74¡24.85 mm
3 compared with 169.19¡38.39 mm
3;
P50.023) and 42% (130.43¡37.92 mm
3 compared with
224.85¡34.16 mm
3; P50.011) in layers II and V respectively
(Figure 4D).However,nosignificantdeclineineithersurfaceor
volume was found in layers I, III and VI.
Finally, at later ages (12 months), the decrease in either
surface or volume was restricted to layer VI but had a similar
significance. 3xTg-AD animals showed a decrease in GFAP
surface by 43% (418.81¡53.84 mm
2 compared with
739.91¡56.20 mm
2; P50.007) and in volume by 49%
Figure 3 Comparison of astrocytic GFAP surface and volume in the whole
EC of non-Tg and 3xTg-AD animals across ages
The histograms show a comparison of GFAP (A) surface, (B) volume and (C)
body volume in the global EC at the age of 1, 3, 6, 9 and 12 months between
3xTg-AD and non-Tg animals. Results are means¡S.E.M. (*P#0.05 compared
with the age-matched non-Tg control). Confocal micrographs show astrocytic
atrophy in 3xTg-AD at 1 month (E) and 12 months (G) compared with the
control animals (D and F).
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275(149.03¡23.85 mm
3 compared with 290.03¡29.20 mm
3;
P50.004; Figures 4E and 4F).
Astrocytic atrophy in the EC is not associated
with loss of GFAP-IR astrocytes
The density of astrocytes in the EC and in different layers
of EC of 3xTg-AD mice when compared with non-Tg mice
was constant at all ages (Figure 2E). The distribution of GFAP-
IR cells throughout the EC was also similar at all ages
(Figure 2).
Rare association of astrocytes with Ab plaques
and absence of hypertrophic reaction
The presence of intraneuronal Ab accumulation in EC is
evident from 9 months of age, although plaques and
extracellular aggregates are not present until 12 months
of age (Figure 5). However, notwithstanding Ab accumula-
tion, GFAP-IR astrocytes rarely appear to be associated
with Ab-positive neurons, extracellular Ab aggregates or
SPs in the 3xTg-AD animals. All in all, less than 5% of
astrocytes were located at a distance ,50 mm to the SP.
Most importantly, however, we failed to observe any
signs of hypertrophy in EC astrocytes in 3xTg-AD animals
at all ages; astroglial cells always demonstrated atrophic
morphology.
DISCUSSION
The EC is regarded as a funnel for cortico-hippocampal
information transfer and integration, playing an essential role
in cognition and memory (Kerr et al., 2007; Canto et al., 2008;
Coutureau and Di Scala, 2009). In the present study, for
the first time we present evidence indicating an early (from
1 month of age) atrophy of astrocytes in the EC of 3xTg-AD
mice; this atrophy being sustained through more advanced
ages (up to 12 months). This atrophic remodelling occurred
in the superficial and deep layers at early and middle age
(1–6 months), although at later ages (12 months) it remained
only in the deeper layers. The morphological atrophy of
astroglia is not accompanied by an astrocytic loss at all ages.
The generalized atrophy characterized by a major reduction
in astrocytic primary branches and massive reduction in
secondary and distal processes in the EC appears in very
young 3xTg-AD animals (1 months old), which did not show
yet any signs of AD pathology. This atrophic appearance
remains in later ages (12 months), distinguished by deve-
loped Ab plaques and NFTs, which are confirmed by the
immunoreactivity of Ab and phosphorylated tau protein
(Supplementary Figure S1 at http://www.asnneuro.org/an/
003/an003e071add.htm; Oddo et al., 2003b; Rodrı ´guez et al.,
2009b). Consistent reduction in the GFAP expression is in
agreement with our previous observations of generalized
atrophy of astrocytes in the HC, which similarly appear before
the neuropathological marks (from 9 months) and are
sustained in later ages (up to 18 months; Rodrı ´guez et al.,
2009b; Olabarria et al., 2010). Although some post-mortem
studies have revealed hypertrophic astrocytes, characteristic of
astrogliosis in the EC of AD human patients (Muramori et al.,
1998; Porchet et al., 2003, Vanzani et al., 2005), this is only
Figure 4 Comparison of astrocytic GFAP EC surface and volume at
different ages
The histograms show decreased GFAP surface (A, C, E) and volume (B, D, F)
within specific layers between 3xTg-AD animals at the ages of 1, 6 and 12
months respectively. Results are means¡S.E.M. (*P#0.05; **P#0.01
compared with the age-matched non-Tg control).
Figure 5 Distribution and relationship of GFAP immunoreactive astrocytes
and b-amyloid presence
Confocal images of dual labelling of GFAP (red) and Ab (green) show that
GFAP-IR astrocytes are distant from intracellular Ab deposits (with a distance
of 86 mm) at 12 months and distant from the Ab plaques (with a distance of
125 mm) at 18 months. Arrowheads indicate astrocytes.
C.-Y. Yeh and others
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also showed disrupted processes and dynamic properties
(Colombo et al., 2002). Furthermore, microarray analysis also
showed a decrease in gene transcription of astrocytic
cytoskeleton proteins in AD, implying a down-regulation of
the astrocytic cytoskeleton (Simpson et al., 2011). At the same
time, the density of GFAP-IR cells remains constant at all ages
in both the control and 3xTg-AD. This indicates that neither
aging nor AD pathology triggers cell loss. These data again
correspond to our previous study and argue against the
prominent astroglial proliferative response in the 3xTg-AD
brain (Olabarria et al., 2010).
Astrocytic atrophy in the EC occurred very early, at
1 month of age. This is somewhat similar to the general
observation that the AD pathology is manifested by Ab
accumulation, which begins in neocortex and rhinal cortices,
including the EC, subsequently progressing to the HC and
eventually appearing in all subcortical areas (Braak and Braak,
1997; Thal et al., 2000). The formation of neurofibrillary
tangles initiates in the transentorhinal as well as entorhinal
cortices, advancing to the HC through the perforant path and
neighbouring cortical regions (Braak et al., 1999). The
spatiotemporal occurrence of astroglial atrophy is therefore
consistent with pathological hallmarks of AD, indicating that
the EC is the region first affected by AD pathology. The
evident changes in entorhinal astrocytes appear within layers
II, III and VI at early age (1 month); layers II and V are affected
at middle age (6 months), while they are restricted in layer
VI at later ages (12 months). Nevertheless, it should be noted
that there is no recovery of atrophic astrocytes in transgenic
mice in the superficial layers at later ages but a decrease in
GFAP in non-Tg controls, implying an aging effect on control
animals (Figure 3).
Astroglia sustain multiple functions, including balance of
neurotransmitters, release of trophic factors, metabolic
support and extracellular ion buffering, all of which maintain
brain physiology and support neuronal connectivity (Danbolt,
2001; Nedergaard et al., 2003; Wang and Bordey, 2008;
Verkhratsky et al., 2010, 2011). In addition, astrocytes are able
to sense synaptic activity, regulate synaptic plasticity and
synchronize neuronal networks, thus being involved in
conscience and cognitive processes (Araque et al., 1999;
Fellin et al., 2004; Henneberger et al., 2010; Lalo et al., 2006,
2011). Finally, by virtue of astrogliosis, astrocytes form the
innate brain defence system, localizing the lesions and
assisting in pathological remodelling of the affected circuitry
(Sofroniew, 2009). Early astroglial atrophy observed in EC
may result in reduced astroglial coverage of synapses and
thus may appear to be a key factor in altered synaptic
connectivity (Rodrı ´guez et al., 2009b; Verkhratsky et al.,
2010). In consequence, the synaptic condition and/or activity
may be affected, causing synaptic remodelling, altered
synaptic connections and network activity. It is likely that
this early astrocytic alteration leads to compromised EC
output to other areas, especially the HC that receives
innervation from both the superficial and deep layers of
the EC (Figure 1). In fact, there is no significant neuronal
loss in memory-associated areas, such as the EC and HC, in
the 3xTg-AD animal model (Oddo et al., 2003a, 2003b; Rohn
et al., 2008; Bittner et al., 2010). Nonetheless, loss of synapses
and/or dendritic spines as well as compromised long-term
potentiation have been detected in several brain regions,
suggesting impaired synaptic connectivity and functions in
this animal model (Oddo et al., 2003a; Bertoni-Freddari et al.,
2008; Bittner et al., 2010; Noristani et al., 2011). Therefore
the astrocytic atrophy in the EC may underlie synaptic
pathology being the basis of cognitive and memory
impairment at the early stages of the AD.
In contrast with the HC (Olabarria et al., 2010), arrival of
Ab depositions and SPs in the EC does not trigger astrolgiotic
reaction at least from the morphological criteria. We failed to
observe a close association of astrocytes with SPs; nor did
we find any signs of astroglial hypertrophy. This peculiar
indifference of EC astrocytes to the AD-specific lesion may
underlie the particular vulnerability of the EC to the AD-like
pathology and provide an explanation of why EC is the first
brain region to be affected in the course of AD. Obviously,
further studies are required to extend the findings from the
AD animal model to human pathology.
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